Association between serum sex hormone levels and prostate cancer: Effect of prostate cancer on serum testosterone levels

Future Oncology

Volumn 5, Issue 7, 2009, Pages 1005-1013

  Imamoto, Takashi ^a   Suzuki, Hiroyoshi ^a   Utsumi, Takanobu ^a   Endo, Takumi ^a   Takano, Makoto ^a   Yano, Masashi ^a   Kawamura, Koji ^a   Kamiya, Naoto ^a   Nihei, Naoki ^a   Naya, Yukio ^a   Ichikawa, Tomohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

5 reductase inhibitors; Dihydrotestosterone; Pathological findings; Prognosis; Risk; Tumor grade

Indexed keywords

4,7BETA DIMETHYL 4 AZACHOLESTAN 3 ONE; ANDROGEN; ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; SEX HORMONE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADVANCED CANCER; ANDROGEN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; HORMONE BLOOD LEVEL; HUMAN; NONHUMAN; ORGAN GROWTH; ORGANOGENESIS; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE DISEASE; REVIEW; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; BLOOD; MALE; PATHOLOGY; PROSTATE TUMOR;

HUMANS; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 73349103485     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.82     Document Type: Review

References (76)

1. Chan JM, Stampfer MJ, Giovannucci EL: What causes prostate cancer? A brief summary of the epidemiology. Semin. Cancer Biol. 8, 263-273 (1998).
2. Ekman P: Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Eur. Urol. 35, 362-369 (1999).
3. Morgentaler A: Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur. Urol. 52, 623-625 (2007).
4. Stattin P, Lumme S, Tenkanen L et al.: High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int. J. Cancer 108, 418-424 (2004).
5. Endogenous Hormones and Prostate Cancer Collaborative Group: Endogenous sex hormones and prostate cancer; a collaborative analysis of 18 prospective studies. J. Natl Cancer Inst. 100, 170-183 (2008).
6. Morgentaler A: Testosterone and prostate cancer: an historical perspective on a modern myth. Eur. Urol. 50, 935-939 (2006).
7. Freedland SJ, Isaacs WB, Platz EA et al.: Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J. Clin. Oncol. 23, 7546-7554 (2005).
8. Chen SS, Chen KK, Lin AT et al.: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int. 89, 710-713 (2002).
9. Hsing AW: Hormones and prostate cancer: what's next? Epidemiol. Rev. 23, 42-58 (2001).
10. Huggins C, Stevens RE, Hodges CV: Studies on prostatic cancer: II. The effect of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209-212 (1941).
11. Eaton NE, Reeves GK, Appleby PN, Key TJ: Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br. J. Cancer 80, 930-934 (1999).
12. Kaaks R, Lukanova A, Sommersberg B: Plasma androgens, IGF-I, body size and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis. 3, 157-172 (2000).
13. Hsing AW, Reichardt JK, Stanczyk FZ: Hormones and prostate cancer: current perspectives and future directions. Prostate 52, 213-235 (2002).
14. Parsons JK, Carter HB, Platz EA et al.: Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol. Biomarkers Prev. 14, 2257-2260 (2005).
15. Heikkila R, Aho K, Heliovaara M et al.: Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 86, 312-315 (1999).
16. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ: Prospective study of sex hormone levels and risk of prostate cancer. J. Natl Cancer Inst. 88, 1118-1126 (1996).
17. Hsing AW, Comstock GW: Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2, 27-32 (1993).
18. Guess HA, Friedman GD, Sadler MC et al.: 5 α-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol. Biomarkers Prev. 6, 21-24 (1997).
19. Vatten LJ, Ursin G, Ross RK et al.: Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomarkers Prev. 6, 967-969 (1997).
20. Dorgan JF, Albanes D, Virtamo J et al.: Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol. Biomarkers Prev. 7, 1069-1074 (1998).
21. Svatek RS, Shulman MJ, Benaim EA, Rogers TE, Margulis V: Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis. J. Urol. 179, 2192-2196 (2008).
22. Rhoden EL, Riedner CE, Morgentaler A: The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J. Urol. 179, 1741-1745 (2008). • Interesting new information on the ratio of testosterone:prostate-specific antigen (PSA) as an independent predictor of prostate cancer (PCa) in hypogonadal men.
23. Yano M, Imamoto T, Suzuki H et al.: The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur. Urol. 51, 293-295 (2007).
24. Kato T, Suzuki H, Komiya A et al.: Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer. Int. J. Urol. 13, 915-919 (2006).
25. Kawamura K, Suzuki H, Kamiya N et al.: Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/ml. Int. J. Urol. 15, 598-603 (2008).
26. Utsumi T, Kawamura K, Suzuki H et al.: External validation and head-to-head comparison of Japanese and Western prostate biopsy nomograms using Japanese data sets. Int. J. Urol. 16, 416-419 (2009).
27. Ross RK, Pike MC, Coetzee GA et al.: Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 58, 4497-4504 (1998).
28. Ross RK, Bernstein L, Lobo RA et al.: 5-α-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339, 887-889 (1992).
29. Morgentaler A, Traish AM: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur. Urol. 55, 310-321 (2009). •• Proposes the saturation model as a new concept to explain the relationship between testosterone and PCa.
30. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med. 350, 482-492 (2004).
31. Bhasin S, Singh AB, Mac RP et al.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J. Androl. 24, 299-311 (2003).
32. Barqawi AB, Crawford ED: Testosterone replacement therapy and the risk of prostate cancer: a perspective view. Int. J. Impot. Res. 17, 462-463 (2005).
33. Morgentaler A, Rhoden EL: Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology 68, 1263-1267 (2006).
34. Thompson IM, Pauler DK, Goodman PJ et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4 ng per milliliter. N. Engl. J. Med. 350, 2239-2246 (2004).
35. Isbarn H, Pinthus JH, Marks LS et al.: Testosterone and prostate cancer: revisiting old paradigms. Eur. Urol. (2009) (Epub ahead of print). •• Highlights the role of serum androgen levels in PCa risk.
36. Hoffman MA, DeWolf WC, Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? J. Urol. 163, 824-827 (2000).
37. Schatzl G, Madersbacher S, Thurridl T et al.: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47, 52-58 (2001).
38. Platz EA, Leitzmann MF, Rifai N et al.: Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol. Biomarkers Prev. 14, 1262-1269 (2005).
39. Ribeiro M, Ruff P, Falkson G: Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am. J. Clin. Oncol. 20, 605-608 (1997).
40. Massengill JC, Sun L, Moul JW et al.: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J. Urol. 169, 1670-1675 (2003).
41. Imamoto T, Suzuki H, Fukasawa S et al.: Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur. Urol. 47, 308-312 (2005).
42. Isom-Batz G, Bianco Jr FJ, Kattan MW et al.: Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J. Urol. 173, 1935-1937 (2005).
43. Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G: Association between prostate cancer and serum testosterone levels. Prostate 53, 179-182 (2002).
44. Ide H, Yasuda M, Nishio K et al.: Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res. 28, 2487-2492 (2008).
45. Teloken C, Da Ros CT, Caraver F et al.: Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J. Urol. 174, 2178-2180 (2005).
46. Partin AW, Pound CR, Clemens JQ et al.: Serum PSA after anatomic radical retropubic prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. North Am. 20, 713-725 (1993).
47. Han M, Partin AW, Pound CR et al.: Long-term biochemical disease-free and cancer specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 28, 555-565 (2001).
48. Miller LR, Partin AW, Chan DW et al.: Influence of radical prostatectomy on serum hormone levels. J. Urol. 160, 449-453 (1998).
49. Lukkarinen O, Hammond GL, Kontturi M et al.: Peripheral and prostatic vein steroid concentrations in benign prostatic hypertrophy patients before and after removal of the adenoma. Scand. J. Urol. Nephrol. 14, 225-227 (1980).
50. Madersbacher S, Schatzl G, Bieglmayer C et al.: Impact of radical prostatectomy and TURP on the hypothalamic - pituitary - gonadal hormone axis. Urology 60, 869-874 (2002).
51. Ghosh PK, Ghosh D, Ghosh P, Chaudhuri A: Effects of prostatectomy on testicular androgenesis and serum levels of gonadotropins in mature albino rats. Prostate 26, 19-22 (1995).
52. Yamamoto S, Yonese J, Kawakami S et al.: Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur. Urol. 52, 696-701 (2007).
53. Phadke MA, Vanage GR, Sheth AR: Circulating levels of inhibin, prolactin, TSH, LH, and FSH in benign prostatic hypertrophy before and after tumor resection. Prostate 10, 115-122 (1987).
54. Imamoto T, Suzuki H, Yano M et al.: Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients? Prostate Cancer Prostatic Dis. 12, 78-82 (2009).
55. Lokeshwar BL, Hurkadli KS, Sheth AR, Block NL: Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. Cancer Res. 53, 4855-4859 (1993).
56. Sheth AR, Garde SV, Mehta MK, Shah MG: Hormonal modulation of biosynthesis of prostatic specific antigen, prostate specific acid phosphatase and prostatic inhibin peptide. Indian J. Exp. Biol. 30, 157-161 (1992).
57. Risbridger GP, Shibata A, Ferguson KL et al.: Elevated expression of inhibin A in prostate cancer. J. Urol. 171, 192-196 (2004).
58. Imamoto T, Suzuki H, Akakura K et al.: Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr. J. 48, 573-578 (2001).
59. Jorgensen T, Kanagasingam Y, Kaalhus O et al.: Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2. J. Urol. 158, 164-170 (1997).
60. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway MS, Smith JA: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 265, 618-621 (1991).
61. Iversen P, Rasmussen F, Christensen IJ: Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand. J. Urol. Nephrol. Suppl. 157, 41-47 (1994).
62. Harman SM, Metter EJ, Tobin JD et al.: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86, 724-731 (2001).
63. Vermeulen A: Andropause. Maturitas 34, 5-15 (2000).
64. Leifke E, Gorenoi V, Wichers C et al.: Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin. Endocrinol. 53, 689-695 (2000).
65. Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K: Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. J. Urol. 176, 1387-1391 (2006).
66. Thompson IM, Goodman PJ, Tangen CM et al.: The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224 (2003).
67. Carver BS, Kattan MW, Scardino PT, Eastham JA: Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int. 95, 509-512 (2005).
68. Rubin MA, Allory Y, Molinie V et al.: Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 66, 930-934 (2005).
69. Tindall DJ, Rittmaster RS: The rationale for inhibiting 5α-reductase isoenzymes in the prevention and treatment of prostate cancer. J. Urol. 179, 1235-1242 (2008). •• Highlights the relevance of 5α-reductase inhibition in PCa treatment.
70. Festuccia C, Gravina GL, Muzi P et al.: Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386. J. Urol. 180(1), 367-372 (2008). • Interesting new information on the antitumor effect of 5α-reductase inhibitors.
71. Andriole G, Bostwick D, Brawley O et al.: Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J. Urol. 172, 1314-1317 (2004).
72. Fleshner N, Gomella LG, Cookson MS et al.: Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp. Clin. Trials 28, 763-769 (2007).
73. Bonkhoff H, Berges R: The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur. Urol. 55, 533-542 (2009). • Highlights the role of estrogen receptors in PCa progression and prevention.
74. Price D, Stein B, Sieber P et al.: Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, Phase IIB clinical trial. J. Urol. 176, 965-970 (2006).
75. Prehn RT: On the prevention and therapy of prostate cancer by androgen administration. Cancer Res. 59, 4161-4164 (1999).
76. Algarte-Genin M, Cussenot O, Costa P: Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur. Urol. 46, 285-295 (2004).